[A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
BACKGROUND
Bromocriptine and pergolide are the two dopamine agonists most often used in Parkinson's disease. Few comparative studies of the efficacy of both compounds are available.


OBJECTIVE
To compare the relative efficacy of bromocriptine and pergolide in patients with Parkinson's disease and intermediate stages of evolution.


METHODS
Open label study of 5-months of duration. The first agonist was given for two months and, after a period of substitution of one month, the second agonist was also maintained for two months.


RESULTS
Pergolide was more effective than bromocriptine for global scores of the UPDRS, total motor scores, clinical symptoms, akinesia and rigidity. Both compounds were equal effective for the treatment of tremor and fluctuations. Both agonists produced similar side effects.


CONCLUSIONS
At the ration 1/10 mg/day pergolide was more effective than bromocriptine in patients with Parkinson's disease at intermediate stages of evolution.
de Yébenes
J G
JG
Servicio de Neurología, Fundación Jiménez Díaz, Madrid, España.
García-Ruiz
P J
PJ
Sánchez-Pernaute
R
R
D000368:Aged; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D009127:Muscle Rigidity / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D014202:Tremor / Q000188:drug therapy
D018491:Dopamine Agonists; D010479:Pergolide; D001971:Bromocriptine; D007980:Levodopa